Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sung, Ki-Chul | - |
dc.contributor.author | Hong, Soon Jun | - |
dc.contributor.author | Rhee, Moo-Yong | - |
dc.contributor.author | Jeong, Myung-Ho | - |
dc.contributor.author | Kim, Dae-Hee | - |
dc.contributor.author | Lim, Sang-Wook | - |
dc.contributor.author | Park, Kyungil | - |
dc.contributor.author | Lee, Jin Bae | - |
dc.contributor.author | Kim, Seok-Yeon | - |
dc.contributor.author | Cho, Jin-Man | - |
dc.contributor.author | Cho, Goo-Yeong | - |
dc.contributor.author | Heo, Jung-Ho | - |
dc.contributor.author | Kim, Sang-Hyun | - |
dc.contributor.author | Lee, Hae-Young | - |
dc.contributor.author | Kim, Weon | - |
dc.contributor.author | Cho, Deok-Kyu | - |
dc.contributor.author | Park, Sungha | - |
dc.contributor.author | Shin, Jinho | - |
dc.contributor.author | Pyun, Wook-Bum | - |
dc.contributor.author | Kwon, Kihwan | - |
dc.contributor.author | Rha, Seung-Woon | - |
dc.contributor.author | Jung, Jin-A | - |
dc.date.accessioned | 2023-07-05T04:22:38Z | - |
dc.date.available | 2023-07-05T04:22:38Z | - |
dc.date.created | 2023-05-03 | - |
dc.date.issued | 2023-04 | - |
dc.identifier.issn | 1524-6175 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/186383 | - |
dc.description.abstract | We compared the efficacy and safety of third-standard-dose triple and third-standard-dose dual antihypertensive combination therapies in patients with mild to moderate hypertension. This was a phase II multicenter, randomized, double-blind, parallel-group trial. After a 4-week placebo run-in period, 245 participants were randomized to the third-dose triple combination (ALC group; amlodipine 1.67 mg + losartan potassium 16.67 mg + chlorthalidone 4.17 mg) or third-dose dual combination (AL group; amlodipine 1.67 mg + losartan potassium 16.67 mg, LC group; losartan potassium 16.67 mg + chlorthalidone 4.17 mg, AC group; amlodipine 1.67 mg + chlorthalidone 4.17 mg) therapy groups and followed up for 8 weeks. The mean systolic blood pressure (BP) reduction was -18.3 ± 13.2, -13.0 ± 13.3, -16.3 ± 12.4, and -13.8 ± 13.2 mmHg in the ALC, AL, LC, and AC groups, respectively. The ALC group showed significant systolic BP reduction compared to the AL and AC groups at weeks 4 (P =.010 and P =.018, respectively) and 8 (P =.017 and P =.036, respectively). At week 4, the proportion of systolic BP responders was significantly higher in the ALC group (42.6%) than in the AL (22.0%), LC (23.3%), and AC (27.1%) groups (P =.013, P =.021, and P =.045, respectively). At week 8, the proportion of systolic and diastolic BP responders was significantly higher in the ALC group (59.7%) than in the AL (39.3%) and AC (42.4%) groups (P =.022 and P =.049, respectively) at week 8. Third-standard-dose triple antihypertensive combination therapy demonstrated early effective BP control compared to third-standard-dose dual combination therapies, without increasing adverse drug reactions in patients with mild-to-moderate hypertension. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.title | Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Shin, Jinho | - |
dc.identifier.doi | 10.1111/jch.14656 | - |
dc.identifier.scopusid | 2-s2.0-85153631049 | - |
dc.identifier.wosid | 000986688500005 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL HYPERTENSION, v.25, no.5, pp.429 - 439 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL HYPERTENSION | - |
dc.citation.title | JOURNAL OF CLINICAL HYPERTENSION | - |
dc.citation.volume | 25 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 429 | - |
dc.citation.endPage | 439 | - |
dc.type.rims | ART | - |
dc.type.docType | Article; Early Access | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.subject.keywordPlus | BLOOD-PRESSURE CONTROL | - |
dc.subject.keywordPlus | THERAPEUTIC INERTIA | - |
dc.subject.keywordPlus | QUADRUPLE COMBINATION | - |
dc.subject.keywordPlus | INITIAL TREATMENT | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | AMLODIPINE | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | PERINDOPRIL | - |
dc.subject.keywordAuthor | combination therapy | - |
dc.subject.keywordAuthor | hypertension | - |
dc.subject.keywordAuthor | low-dose | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/jch.14656 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.